Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.

This article proposes that androgenic alopecia might be an evolutionary mechanism for reducing prostate cancer risk by enhancing UV absorption, rather than being a risk factor.

This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.

This study found that in rodent models, the ability of D1 dopamine receptor activation to impair sensory gating is facilitated by 5α-reductase type 1, which produces allopregnanolone.

This article reviews the negative impact of hair loss on self-esteem and quality of life across cultures without presenting new findings.

New method effectively analyzes finasteride and its stability.

This review discusses pharmacologic and non-pharmacologic treatments for androgenetic alopecia, noting that current medications like finasteride and minoxidil can slow hair loss but only partially restore hair growth, with early treatment offering better outcomes.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

This study developed a new competitive 5alpha-reductase inhibitor with an IC(50) of 0.84 microM using a novel chemical structure.

This meta-analysis reported that finasteride 1 mg/day significantly increased hair count in male androgenetic alopecia compared to placebo, but highlighted persistent sexual side effects and associated depression risk.

This review discusses the various treatment options for male and female pattern hair loss and provides no new clinical results; the authors outline the most effective strategies based on existing evidence.

In this review, the authors explored current and novel treatment options for androgenetic alopecia, noting both FDA-approved pharmacologic treatments like Minoxidil and Finasteride and various non-pharmacologic and surgical methods, including hair transplantation and scalp micro-pigmentation.

This study found that manipulating AKR1D1 expression in human liver cells effectively regulates glucocorticoid clearance and receptor activation, highlighting its role in liver-specific steroid hormone regulation.

This article reviews pharmacologic treatments for pattern hair loss and emphasizes integrating them with surgical and nonmedical options, but it does not present new clinical findings.

This review discusses clinical variations, laboratory testing, and treatments for female-pattern alopecia, including finasteride, but reports no new clinical findings; the authors emphasize managing stress and psychological impacts.

This review examines recent advancements in analytical techniques used to quantify dutasteride, a medication for enlarged prostate, in various biological samples and its commercial forms, emphasizing methods such as HPTLC, GC-MS, and HPLC.

This review details contemporary medical management options for benign prostatic hyperplasia, highlighting the expanding role of phosphodiesterase-5 inhibitors and beta-3 agonists, but reports no new clinical findings.

The authors discuss BPH treatment options and highlight that while medications can manage symptoms, recent minimally invasive procedures may offer promise for elderly males who are not surgical candidates or wish to avoid surgery.

This review examines recent approvals and emerging treatments for androgenetic alopecia, discussing newly approved drugs like Propecia and Rogaine Extra Strength 5%, but without presenting new clinical results.

This review highlights that natural DHT blockers like saw palmetto and pumpkin seed oil show promise in managing androgenetic alopecia, though clinical data varies, and further research is needed to confirm their efficacy and safety in comparison to conventional pharmaceuticals.

This study found that men with androgenetic alopecia have different scalp biophysical characteristics in androgen-sensitive areas compared to non-sensitive areas and healthy controls.

In this study, pregnenolone was found to dose-dependently reduce L-DOPA-induced dyskinesias in a rat model of Parkinson's disease, suggesting its potential as a therapeutic target for these dyskinesias.

This review discusses the preventable nature of many cancers due to modifiable risk factors and emphasizes the importance of preventive oncology in reducing the global cancer burden; it reports no new clinical results.

This study reviewed evidence for six minimally invasive treatments for androgenetic alopecia, finding consistent support for platelet-rich plasma and topical finasteride, while other options like microneedling and intradermal dutasteride showed promise but need further and standardized research.

This review highlights the potential of nanotechnology in enhancing the treatment of androgenetic alopecia by facilitating targeted drug delivery, improving drug stability, and increasing concentration at target sites, although clinical validation and scalable manufacturing are needed for practical implementation.

Nutrition plays a key role in managing skin disorders, with specific dietary changes helping improve conditions like acne, dermatitis, psoriasis, alopecia, and skin cancer.

This review summarizes recent advances in alopecia management, focusing on combining synthetic and herbal therapies with innovative drug delivery systems like nanocarriers to enhance effectiveness and reduce side effects, while noting challenges with skin penetration and bioavailability.

Coconut oil boosts testosterone but doesn't fully trigger reproductive maturity in pufferfish.

This review provides an overview of the risks and side effects associated with common medications used to treat benign prostatic hyperplasia, highlighting the importance for clinicians and patients to discuss these aspects for informed decision-making.

This study identified that derivatives 4, 4b, and 4c strongly inhibited the enzyme type 1 5α-reductase and decreased reproductive organ weights in hamsters, suggesting potential as prodrugs for prostate tumor growth inhibition.